Biotech market provides dose of optimism
Covid-19 has shone a spotlight on biotechnology investment opportunities, drawing attention from new corners of the PE world. But exciting new opportunities also come with fresh challenges, writes Alessia Argentieri
More on Healthcare
Gyrus Capital acquires LRE Medical from KPS-backed AIS Global
Carve-out of German diagnostic equipment manufacturer comes over two years after first sale attempt
Forbion raises combined EUR 1.35bn for venture and growth funds
Ventures Fund VI closes on EUR 750m and Growth Opportunities II on EUR 600m with both upsized by over 60%
EQT closes LSP Dementia on EUR 260m hard cap
Series A-focused fund exceeded its EUR 100m target and extended fundraising after increased LP interest in its strategy
Ardian reinvests in Neopharmed alongside NB Renaissance
French GP will move stake from fund VI to VII; additional capital allows for European M&A
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds